Heron Therapeutics (HRTX) News Today → Executive Order To Wipe Out Your Bank Accounts (From Oasis Gold) (Ad) Free HRTX Stock Alerts $3.58 -0.02 (-0.56%) (As of 09:46 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 7 at 7:58 AM | americanbankingnews.comHeron Therapeutics (NASDAQ:HRTX) Trading Up 5.8%June 3, 2024 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest Up 10.9% in MayHeron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 30,270,000 shares, a growth of 10.9% from the April 30th total of 27,290,000 shares. Based on an average daily trading volume, of 2,410,000 shares, the days-to-cover ratio is presently 12.6 days.May 31, 2024 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Hits New 52-Week High at $3.65Heron Therapeutics (NASDAQ:HRTX) Sets New 12-Month High at $3.65May 30, 2024 | marketbeat.comFranklin Resources Inc. Sells 553,315 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)Franklin Resources Inc. lowered its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 8.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,404,795 shares of the biotechnology company's stock after selling 5May 29, 2024 | finanznachrichten.deHeron Therapeutics, Inc.: Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF Vial Access Needle ("VAN")May 29, 2024 | baystreet.caHeron Dips on Progress Re: ZynreliefMay 29, 2024 | markets.businessinsider.comHeron Therapeutics Submits Prior Approval Supplement To FDA For Zynrelef VANMay 29, 2024 | finance.yahoo.comPleasing Signs As A Number Of Insiders Buy Heron Therapeutics StockMay 29, 2024 | prnewswire.comHeron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")May 20, 2024 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Reaches New 12-Month High at $3.36Heron Therapeutics (NASDAQ:HRTX) Reaches New 12-Month High at $3.36May 17, 2024 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Expected to Post FY2026 Earnings of $0.20 Per ShareHeron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Equities researchers at Capital One Financial upped their FY2026 earnings estimates for shares of Heron Therapeutics in a research note issued on Wednesday, May 15th. Capital One Financial analyst T. Chiang now expects that the biotechnologyMay 16, 2024 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $5.00 price objective on shares of Heron Therapeutics in a research report on Thursday.May 16, 2024 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest Up 7.3% in AprilHeron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) was the target of a large growth in short interest in April. As of April 30th, there was short interest totalling 27,290,000 shares, a growth of 7.3% from the April 15th total of 25,430,000 shares. Based on an average trading volume of 2,350,000 shares, the days-to-cover ratio is presently 11.6 days.May 11, 2024 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Monaco Asset Management SAMMonaco Asset Management SAM grew its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 219.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,226,475 shares of the biotechnology coMay 10, 2024 | marketbeat.comQ2 2024 EPS Estimates for Heron Therapeutics, Inc. Raised by Northland Capmk (NASDAQ:HRTX)Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Equities research analysts at Northland Capmk lifted their Q2 2024 earnings estimates for shares of Heron Therapeutics in a research report issued to clients and investors on Wednesday, May 8th. Northland Capmk analyst C. Byrnes now anticipatMay 9, 2024 | finance.yahoo.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Just Released Its First-Quarter Earnings: Here's What Analysts ThinkMay 8, 2024 | finance.yahoo.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call TranscriptMay 8, 2024 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Rating Reiterated by Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $5.00 price objective on shares of Heron Therapeutics in a research note on Wednesday.May 8, 2024 | finance.yahoo.comHeron Therapeutics Inc (HRTX) Q1 2024 Earnings Call Transcript Highlights: Significant ...May 8, 2024 | finance.yahoo.comHeron Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 7, 2024 | seekingalpha.comHeron Therapeutics, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 7, 2024 | finanznachrichten.deHeron Therapeutics, Inc.: Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate UpdatesMay 7, 2024 | markets.businessinsider.comHeron Therapeutics Inc. Q1 Loss decreases, beats estimatesMay 7, 2024 | msn.comHeron Therapeutics GAAP EPS of -$0.02, revenue of $34.67MMay 7, 2024 | finance.yahoo.comHeron Therapeutics Inc (HRTX) Q1 2024 Earnings Overview: Surpasses Revenue EstimatesMay 7, 2024 | prnewswire.comHeron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate UpdatesMay 7, 2024 | markets.businessinsider.comHeron Therapeutics earnings preview: what to expectApril 30, 2024 | marketbeat.comHeron Therapeutics (HRTX) Scheduled to Post Quarterly Earnings on TuesdayHeron Therapeutics (NASDAQ:HRTX) will be releasing earnings before the market opens on Tuesday, May 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=588518)April 25, 2024 | finance.yahoo.comHeron Therapeutics, Inc.'s (NASDAQ:HRTX) Profit OutlookApril 25, 2024 | marketbeat.comEquities Analysts Offer Predictions for Heron Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:HRTX)Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Research analysts at Capital One Financial issued their Q1 2024 earnings per share (EPS) estimates for shares of Heron Therapeutics in a report released on Tuesday, April 23rd. Capital One Financial analyst T. Chiang forecasts that the biotecApril 24, 2024 | prnewswire.comHeron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024April 23, 2024 | msn.comCapital One Initiates Coverage of Heron Therapeutics (HRTX) with Overweight RecommendationApril 23, 2024 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Coverage Initiated at Capital One FinancialCapital One Financial started coverage on Heron Therapeutics in a research report on Tuesday. They set an "overweight" rating and a $6.00 price objective for the company.April 16, 2024 | seekingalpha.comHeron Therapeutics: Zynrelef Potentially Eases Shareholder PainApril 12, 2024 | nasdaq.comCommit To Buy Heron Therapeutics At $2, Earn 22.4% Annualized Using OptionsApril 11, 2024 | prnewswire.comHeron Therapeutics to Host Investor Day on May 15, 2024 in New York CityApril 1, 2024 | marketbeat.comCongress Park Capital LLC Purchases 1,209,500 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)Congress Park Capital LLC increased its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 205.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,798,650 shares of the biotechnology company's stoMarch 28, 2024 | prnewswire.comHeron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 21, 2024 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Shares Pass Above Two Hundred Day Moving Average of $1.67Heron Therapeutics (NASDAQ:HRTX) Stock Passes Above 200 Day Moving Average of $1.67March 16, 2024 | ca.finance.yahoo.comHRTX Apr 2024 1.500 callMarch 14, 2024 | finance.yahoo.comHeron Therapeutics Full Year 2023 Earnings: Beats ExpectationsMarch 14, 2024 | marketwatch.comHeron Therapeutics Soars After 4Q Earnings BeatMarch 13, 2024 | theglobeandmail.comBiotech Finds Mid-Week Success Following Q4 Earnings ReleaseMarch 13, 2024 | markets.businessinsider.comWhy Is Postoperative Pain Focused Heron Therapeutics Stock Trading Higher On Wednesday?March 13, 2024 | finance.yahoo.comQ4 2023 Heron Therapeutics Inc Earnings CallMarch 13, 2024 | finance.yahoo.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2023 Earnings Call TranscriptMarch 13, 2024 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Given New $5.00 Price Target at Needham & Company LLCNeedham & Company LLC increased their target price on shares of Heron Therapeutics from $4.00 to $5.00 and gave the company a "buy" rating in a research note on Wednesday.March 12, 2024 | finance.yahoo.comHeron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate UpdatesMarch 12, 2024 | finance.yahoo.comHeron Therapeutics Inc (HRTX) Exceeds Full-Year Revenue Guidance for 2023March 12, 2024 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Shares Acquired by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. raised its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 100.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,000,000 shares of the biotechnolo Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Executive Order To Wipe Out Your Bank Accounts (Ad)Don't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast. Click Here To Get Your FREE Guide Now! HRTX Media Mentions By Week HRTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HRTX News Sentiment▼0.990.76▲Average Medical News Sentiment HRTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HRTX Articles This Week▼22▲HRTX Articles Average Week Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Stoke Therapeutics News Today Mersana Therapeutics News Today Revance Therapeutics News Today Generation Bio News Today NGM Biopharmaceuticals News Today Amphastar Pharmaceuticals News Today Vera Therapeutics News Today Geron News Today Catalyst Pharmaceuticals News Today Rocket Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HRTX) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold | SponsoredTrump convicted... now what?Unexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored